摘要
目的探讨喹硫平与利培酮治疗难治性抑郁症的疗效与安全性。方法将69例难治性抑郁症分为喹硫平组(35例),利培酮组(34例),所有患者均服用帕罗西汀,观察6周。于治疗前和治疗1周、2周、4周及6周末采用汉密尔顿抑郁量表(HAMD-17)评定疗效,用副反应量表(TESS)评定不良反应。结果喹硫平组显效率为71%,利培酮组为44%。喹硫平组从第2周末起HAMD分低于利培酮组,差异有统计学意义。喹硫平组不良反应相对少。结论喹硫平合并帕罗西汀治疗不伴精神病性症状的难治性抑郁的疗效好,且起效快,不良反应少。
Objective： To explore the efficacy and safety of quetiapine and risperidone in treating refractory depression. Methods： Sixty - nine patients with refractory depression were divided into quetiapine group（n =35） and risperidone group（ n = 34） with basic treatment of paroxetine and followed for 6 weeks. Hamilton depressive scale （HAMD -17 ） and treatment emergent symptom scale （TESS） were used to evaluate the efficacy and side effects at the point of week 1, weeks 2, weeks 4 and weeks 6. Results： The response rate of quetiapine group was 71% and that of risperidone group was 44%. Quetiapine group showed better efficacy and less side effects. Conclusion：Paroxetine with quetiapine in treating depression without psychotic symptoms have better efficacy and less side effects compared with resperidone.
出处
《上海精神医学》
2008年第5期295-297,共3页
Shanghai Archives of Psychiatry
关键词
难治性抑郁
疗效
喹硫平
利培酮
帕罗西汀
Refractory depression Efficacy Quetiapine Risperedone Paroxetine
